Compare QNC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QNC | RGNX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | Canada | United States |
| Employees | 5 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.7M | 418.1M |
| IPO Year | 2026 | 2015 |
| Metric | QNC | RGNX |
|---|---|---|
| Price | $2.82 | $10.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 456.1K | ★ 495.7K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $1.90 | $6.89 |
| 52 Week High | $3.41 | $16.19 |
| Indicator | QNC | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 65.17 |
| Support Level | $2.57 | $7.76 |
| Resistance Level | $2.96 | $10.37 |
| Average True Range (ATR) | 0.18 | 0.54 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 66.67 | 99.53 |
Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.